StudyFinder

An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan (LNP023) in C3 glomerulopathy or idiopathic immune-complex- membranoproliferative glomerulonephritis

Status: Recruiting

This study is about finding out if long-term use of iptacopan (LNP023) is safe and can help others who have C3 Glomerulopathy (C3G) or idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN). This study if for people who have completed either the IC-MPGN Phase 3 CLNP023B12302 “APPARENT” study or the C3G Phase 3 CLNP023B12301 “APPEAR-C3G” study.

I'm interested

Sex: Male or Female
Age Group: Not specified
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• 18 to 100 years old
• diagnosis of IC-MPGN (immune-complex membranoproliferative glomerulonephritis) or C3G (C3 glomerulopathy)
• must have completed the treatment period of the CLNP023X2202, CLNP023B12301 or CLNP023B12302 study on study drug
Exclusion Criteria:

• active systemic bacterial, viral or fungal infection
• history or current diagnosis of ECG abnormalities
• history of HIV or any other immunodeficiency disease
• see link to clinicaltrials.gov for complete exclusion criteria
Conditions:

Kidney, Prostate & Urinary

Keywords:

C3 Glomerulopathy, Glomerulonephritis

Study Contact: Nattawat Klomjit - klomj001@umn.edu
Principal Investigator: Nattawat Klomjit
Phase: PHASE3
IRB Number: STUDY00025118
See this study on ClinicalTrials.gov

Back